These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10688119)

  • 1. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1.
    Evans SM; Kachur AV; Shiue CY; Hustinx R; Jenkins WT; Shive GG; Karp JS; Alavi A; Lord EM; Dolbier WR; Koch CJ
    J Nucl Med; 2000 Feb; 41(2):327-36. PubMed ID: 10688119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
    Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
    Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of new hypoxia markers EF1 and [18F]-EF1.
    Kachur AV; Dolbier WR; Evans SM; Shiue CY; Shiue GG; Skov KA; Baird IR; James BR; Li AR; Roche A; Koch CJ
    Appl Radiat Isot; 1999 Dec; 51(6):643-50. PubMed ID: 10581679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
    Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
    Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode.
    Jenkins WT; Evans SM; Koch CJ
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):1005-17. PubMed ID: 10705024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
    Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
    Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
    J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of [18F]FETNIM: a potential marker for PET.
    Grönroos T; Eskola O; Lehtiö K; Minn H; Marjamäki P; Bergman J; Haaparanta M; Forsback S; Solin O
    J Nucl Med; 2001 Sep; 42(9):1397-404. PubMed ID: 11535732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
    Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
    Lord EM; Harwell L; Koch CJ
    Cancer Res; 1993 Dec; 53(23):5721-6. PubMed ID: 8242628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
    Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
    J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.
    Bading JR; Alauddin MM; Fissekis JD; Shahinian AH; Joung J; Spector T; Conti PS
    J Nucl Med; 2000 Oct; 41(10):1714-24. PubMed ID: 11038003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
    Ali R; Apte S; Vilalta M; Subbarayan M; Miao Z; Chin FT; Graves EE
    PLoS One; 2015; 10(10):e0139425. PubMed ID: 26431331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
    Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
    J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy.
    Busk M; Horsman MR; Jakobsen S; Keiding S; van der Kogel AJ; Bussink J; Overgaard J
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1202-12. PubMed ID: 18313528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
    Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
    Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.